NCT05851989 Study on Prognosis of Acutely Ruptured Intracranial Aneurysms
| NCT ID | NCT05851989 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Haaglanden Medical Centre |
| Condition | Aneurysmal Subarachnoid Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 880 participants |
| Start Date | 2021-07-14 |
| Primary Completion | 2025-07-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 880 participants in total. It began in 2021-07-14 with a primary completion date of 2025-07-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The SPARTA study is a prospective multicenter observational trial in the Netherlands with the aim of identifying the best clinical care in patients with aneurysmal subarachnoidal haemorrhage. Differences in outcome between surgical treatment and endovascular treatment will be explored. Furthermore, cost effectiveness and radiological prognostic factors will be examined.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of subarachnoid haemorrhage on CT-scan or lumbar puncture (in the presence of a negative CT-scan) * Intracranial aneurysm proven within 6 months to be the cause of subarachnoid haemorrhage * Age 18 years or over at presentation. * Written informed consent Exclusion Criteria: * Subarachnoid haemorrhage deemed most likely of 'perimesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging) * Subarachnoid haemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging) * Diagnosis of intracerebral arteriovenous malformations or dural arteriovenous fistula. * No diagnosis of intracranial aneurysm at 6 months after onset of symptoms. * Not mastering the Dutch language
Contact & Investigator
Wouter Moojen, MD, PhD
PRINCIPAL INVESTIGATOR
Haaglanden Medical Center
Frequently Asked Questions
Who can join the NCT05851989 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aneurysmal Subarachnoid Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05851989 currently recruiting?
Yes, NCT05851989 is actively recruiting participants. Contact the research team at r.j.g.vreeburg@lumc.nl for enrollment information.
Where is the NCT05851989 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands, Maastricht, Netherlands, Nijmegen, Netherlands, Rotterdam, Netherlands and 2 additional locations.
Who is sponsoring the NCT05851989 clinical trial?
NCT05851989 is sponsored by Haaglanden Medical Centre. The principal investigator is Wouter Moojen, MD, PhD at Haaglanden Medical Center. The trial plans to enroll 880 participants.